Greater dose-ranging effects on A1C levels than on glucosuria with lx4211, a dual inhibitor of SGLT1 and SGLT2, in patients with type 2 diabetes on metformin monotherapy

Diabetes Care

Volumn 38, Issue 3, 2015, Pages 431-438

  Rosenstock, Julio ^a   Cefalu, William T ^b   Lapuerta, Pablo ^c   Zambrowicz, Brian ^c   Ogbaa, Ike ^c   Banks, Phillip ^c   Sands, Arthur ^c  

^a DALLAS DIABETES AND ENDOCRINE CENTER AT MEDICAL CITY   (United States)

^b PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^c LEXICON PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; HEMOGLOBIN A1C; METFORMIN; PLACEBO; SODIUM GLUCOSE COTRANSPORTER 1; SODIUM GLUCOSE COTRANSPORTER 2; SOTAGLIFLOZIN; (2S,3R,4R,5S,6R)-2-(4-CHLORO-3-(4-ETHOXYBENZYL)PHENYL)-6-(METHYLTHIO)TETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSIDE; GLYCOSYLATED HEMOGLOBIN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BODY MASS; BODY WEIGHT; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL DISEASE; GENE MUTATION; GENITAL TRACT INFECTION; GLUCOSURIA; HEADACHE; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MOUSE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SINUSITIS; SYSTOLIC BLOOD PRESSURE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VAGINA CANDIDIASIS; VAGINITIS; VULVOVAGINITIS; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; MIDDLE AGED; MULTICENTER STUDY; TREATMENT OUTCOME; WEIGHT REDUCTION;

ADULT; AGED; BLOOD GLUCOSE; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLYCOSIDES; GLYCOSURIA; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; SODIUM-GLUCOSE TRANSPORTER 1; SODIUM-GLUCOSE TRANSPORTER 2; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84923502372     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc14-0890     Document Type: Article

References (33)

1. Starke A, Grundy S, McGarry JD, Unger RH. Correction of hyperglycemia with phloridzin restores the glucagon response to glucose in insulindeficient dogs: implications for human diabetes. Proc Natl Acad Sci U S A 1985;82:1544-1546.
2. Rossetti L, Smith D, Shulman GI, Papachristou D, De Fronzo RA. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest 1987;79:1510-1515.
3. Malathi P, Crane RK. Phlorizin hydrolase: A beta-glucosidase of hamster intestinal brush border membrane. Biochim Biophys Acta 1969; 173:245-256.
4. Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: Rationale and clinical prospects. Nat Rev Endocrinol 2012;8:495-502.
5. Bakris GL, Fonseca VA, Sharma K, Wright EM. Renal sodium-glucose transport: Role in diabetes mellitus and potential clinical implications. Kidney Int 2009;75:1272-1277.
6. Zambrowicz B, Freiman J, Brown PM, et al. LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther 2012;92:158-169.
7. Washburn WN, Poucher SM. Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus. Expert Opin Investig Drugs 2013;22:463-486.
8. Gorboulev V, Schurmann A, Vallon V, et al. Na(+)-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucosedependent incretin secretion. Diabetes 2012; 61:187-196.
9. Powell DR, DaCosta CM, Gay J, et al. Improved glycemic control in mice lacking Sglt1 and Sglt2. Am J Physiol Endocrinol Metab 2013;304:E117-E130.
10. Wright EM. Glucose galactose malabsorption. Am J Physiol 1998;275:879-882.
11. Ikumi Y, Kida T, Sakuma S, Yamashita S, Akashi M. Polymer-phloridzin conjugates as an anti-diabetic drug that inhibits glucose absorption through the Na+/glucose cotransporter (SGLT1) in the small intestine. J Control Release 2008;125:42-49.
12. Sakuma S, Teraoka Y, Sagawa T, et al. Carboxyl group-terminated polyamidoamine dendrimers bearing glucosides inhibit intestinal hexose transporter-mediated D-glucose uptake. Eur J Pharm Biopharm 2010;75:366-374.
13. Dobbins R, Chen L, Liu YJ, et al. Glucose transport via SGLT1 is critical for post-prandial GIP secretion in rats and humans. Presented at the 2012 American Diabetes Association annualmeeting, 8- 12 June 2012, Philadelphia, PA. Available at http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=2936&sKey=07aff962-bab8-4955-800c-f731d933d91d&cKey=100e909f-ee72-423a-9292-faa62e9af6e2&mKey=%7B0F70410F-8DF3-49F5-A63D-3165359F5371%7D. Accessed 13 February 2014.
14. Shibazaki T, Tomae M, Ishikawa-Takemura Y, et al. KGA-2727, a novel selective inhibitor of a high-affinity sodium glucose cotransporter (SGLT1), exhibits antidiabetic efficacy in rodent models. J Pharmacol Exp Ther 2012;342:288-296.
15. Powell DR, Smith M, Greer J, et al. LX4211 increases serum GLD-1 PYY levels by reducing SGLT-1 mediated absorption of intestinal glucose. J Pharmacol Exp Ther 2014;350:232-242.
16. Zambrowicz B, Ding ZM, Ogbaa I, et al. Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes. Clin Ther 2013;35:273-285, e7.
17. Zambrowicz B, Ogbaa I, Frazier K, et al. LX4211, a dual SGLT1 and 2 inhibitor, reduced postprandial glucose in a dose timing study in healthy subjects. Clin Ther 2013;35:1162-1173.
18. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007;132: 2131-2157.
19. Batterham RL, Cowley MA, Small CJ, et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 2002;418:650-654.
20. Kaku H, Tajiri Y, Yamada K.Anorexigenic effects of miglitol in concert with the alterations of gut hormone secretion and gastric emptying in healthy subjects. Horm Metab Res 2012;44:312-318.
21. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
22. List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009;32:650-657.
23. Rosenstock J, Aggarwal N, Polidori D, et al.; Canagliflozin DIA 2001 Study Group. Dose-ranging effects of canagliflozin, a sodiumglucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 2012;35:1232-1238.
24. Ferrannini E, Seman L, Seewaldt-Becker E, Hantel S, Pinnetti S, Woerle HJ. A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes. Diabetes Obes Metab 2013;15:721-728.
25. Lapuerta P, Sands A, Ogbaa I, Strumph P, Powell D, Banks P, Zambrowicz B. LX4211, a dual inhibitor of SGLT1/SGLT2, reduces postprandial glucose in patients with type 2 diabetes mellitus and moderate to severe renal impairment (Abstract). Diabetes 2014;63(Suppl. 1A): 132-LB.
26. Chao EC, Henry RR. SGLT2 inhibitionda novel strategy for diabetes treatment. Nat Rev Drug Discov 2010;9:551-559.
27. Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev 2011;91:733-794.
28. Xin B, Wang H. Multiple sequence variations in SLC5A1 gene are associated with glucose-galactose malabsorption in a large cohort of Old Order Amish. Clin Genet 2011;79: 86-91.
29. Nyirjesy P, Zhao Y, Ways K, Usiskin K. Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor. Curr Med Res Opin 2012;28:1173-1178.
30. Stein P. Canagliflozin: An overview of presentations at the American Diabetes Association 2012. Presented at the 72nd Scientific Sessions of the American Diabetes Association, 8-12 June 2012, at the Pennsylvania Convention Center, Philadelphia, Pennsylvania.
31. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: A randomised, doubleblind, placebo-controlled trial. Lancet 2010; 375:2223-2233.
32. Turnbull F; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: Results of prospectivelydesigned overviews of randomised trials. Lancet 2003;362:1527-1535.
33. Draft ICH Consensus Principle. Principles for Clinical Evaluation of New Antihypertensive Drugs E12A [Internet], 2000. Availableathttp://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/E12/Step4/E12-Guideline.pdf. Accessed 26 September 2012.